Aeglea BioTherapeutics, Inc. (AGLE)

Market Cap	48.45M
Revenue (ttm)	1.23M
Net Income (ttm)	-272.56M
Shares Out	4.05M
EPS (ttm)	-71.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,974
Open	11.78
Previous Close	11.86
Day's Range	11.78 - 12.17
52-Week Range	2.66 - 39.00
Beta	2.53
Analysts	Hold
Price Target	20.00 (+64.34%)
Earnings Date	Nov 2, 2023

About AGLE

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline inclu...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2016
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: AGLE

Financial Performance

In 2022, AGLE's revenue was $2.33 million, a decrease of -87.57% compared to the previous year's $18.74 million. Losses were -$83.82 million, 27.4% more than in 2021.

Analyst Forecast

According to 5 analysts, the average rating for AGLE stock is "Hold." The 12-month stock price forecast is $20.0, which is an increase of 64.34% from the latest price.

Price Target

$20.0

(64.34% upside)

Analyst Consensus: Hold